Kodiak Sciences (KOD) Return on Capital Employed (2018 - 2026)
Kodiak Sciences' (KOD) quarterly Return on Capital Employed came in at 84.2% in Q1 2026, down 1429.0% YoY from 6.34% in Q1 2025, and up 14.04% on a QoQ basis from 97.96% in Q4 2025.
Kodiak Sciences (KOD) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 9 years of Return on Capital Employed data on file, last reported at 84.2% in Q1 2026.
- Quarterly Return on Capital Employed fell 1429.0% year-over-year to 84.2% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84.2% (down 1429.0% YoY) and the FY2025 annual result came in at 78.65%, down 2972.0% from the prior year.
- Return on Capital Employed rose to 84.2% in Q1 2026, from 97.96% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 38.99% in Q1 2022 to a low of 114.44% in Q3 2025.
- A 5-year average of 64.43% and a median of 57.56% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 450 bps — and 2025, when it sank 5824 bps.
- Tracing KOD's Return on Capital Employed over 5 years: stood at 53.11% in 2022, then slipped by 11 bps to 58.78% in 2023, then increased by 3 bps to 56.87% in 2024, then slumped by 72 bps to 97.96% in 2025, then gained by 14 bps to 84.2% in 2026.
- The last three Return on Capital Employed figures came in at 84.2% (Q1 2026), 97.96% (Q4 2025), and 114.44% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Kodiak Sciences | 2.60 Bn | 2.60 Bn | - | -107.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -107.78% |
| Mar 31, 2026 | -84.20% |
| Dec 31, 2025 | -97.96% |
| Sep 30, 2025 | -114.44% |
| Jun 30, 2025 | -84.20% |
| Mar 31, 2025 | -69.92% |
| Dec 31, 2024 | -56.87% |
| Sep 30, 2024 | -56.20% |
| Jun 30, 2024 | -53.38% |
| Mar 31, 2024 | -57.56% |
| Dec 31, 2023 | -58.78% |
| Sep 30, 2023 | -57.85% |
| Jun 30, 2023 | -57.88% |
| Mar 31, 2023 | -54.78% |
| Dec 31, 2022 | -53.11% |
| Sep 30, 2022 | -52.43% |
| Jun 30, 2022 | -46.69% |
| Mar 31, 2022 | -38.99% |
| Dec 31, 2021 | -30.82% |
| Sep 30, 2021 | -23.91% |